CN113874046B - 用于抗体-药物缀合物的含有糖苷的肽接头 - Google Patents

用于抗体-药物缀合物的含有糖苷的肽接头 Download PDF

Info

Publication number
CN113874046B
CN113874046B CN202080013223.5A CN202080013223A CN113874046B CN 113874046 B CN113874046 B CN 113874046B CN 202080013223 A CN202080013223 A CN 202080013223A CN 113874046 B CN113874046 B CN 113874046B
Authority
CN
China
Prior art keywords
substituted
alkyl
aryl
group
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080013223.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN113874046A (zh
Inventor
D·拉布卡
J·刘
A·奥贡科亚
R·A·库迪尔卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RP Scherer Technologies LLC
Original Assignee
RP Scherer Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RP Scherer Technologies LLC filed Critical RP Scherer Technologies LLC
Priority to CN202510154419.0A priority Critical patent/CN119896745A/zh
Priority to CN202510154420.3A priority patent/CN119896746A/zh
Publication of CN113874046A publication Critical patent/CN113874046A/zh
Application granted granted Critical
Publication of CN113874046B publication Critical patent/CN113874046B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080013223.5A 2019-01-23 2020-01-22 用于抗体-药物缀合物的含有糖苷的肽接头 Active CN113874046B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202510154419.0A CN119896745A (zh) 2019-01-23 2020-01-22 用于抗体-药物缀合物的含有糖苷的肽接头
CN202510154420.3A CN119896746A (zh) 2019-01-23 2020-01-22 用于抗体-药物缀合物的含有糖苷的肽接头

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795875P 2019-01-23 2019-01-23
US62/795,875 2019-01-23
PCT/US2020/014658 WO2020154437A1 (en) 2019-01-23 2020-01-22 Glycoside-containing peptide linkers for antibody-drug conjugates

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202510154419.0A Division CN119896745A (zh) 2019-01-23 2020-01-22 用于抗体-药物缀合物的含有糖苷的肽接头
CN202510154420.3A Division CN119896746A (zh) 2019-01-23 2020-01-22 用于抗体-药物缀合物的含有糖苷的肽接头

Publications (2)

Publication Number Publication Date
CN113874046A CN113874046A (zh) 2021-12-31
CN113874046B true CN113874046B (zh) 2025-02-28

Family

ID=71736993

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080013223.5A Active CN113874046B (zh) 2019-01-23 2020-01-22 用于抗体-药物缀合物的含有糖苷的肽接头
CN202510154419.0A Pending CN119896745A (zh) 2019-01-23 2020-01-22 用于抗体-药物缀合物的含有糖苷的肽接头
CN202510154420.3A Pending CN119896746A (zh) 2019-01-23 2020-01-22 用于抗体-药物缀合物的含有糖苷的肽接头

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202510154419.0A Pending CN119896745A (zh) 2019-01-23 2020-01-22 用于抗体-药物缀合物的含有糖苷的肽接头
CN202510154420.3A Pending CN119896746A (zh) 2019-01-23 2020-01-22 用于抗体-药物缀合物的含有糖苷的肽接头

Country Status (8)

Country Link
US (1) US20220226490A1 (cg-RX-API-DMAC10.html)
EP (1) EP3914262A4 (cg-RX-API-DMAC10.html)
JP (2) JP7550768B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210119450A (cg-RX-API-DMAC10.html)
CN (3) CN113874046B (cg-RX-API-DMAC10.html)
AU (1) AU2020210919B2 (cg-RX-API-DMAC10.html)
CA (1) CA3127098A1 (cg-RX-API-DMAC10.html)
WO (1) WO2020154437A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154437A1 (en) * 2019-01-23 2020-07-30 R.P. Scherer Technologies, Llc Glycoside-containing peptide linkers for antibody-drug conjugates
MX2023005979A (es) * 2020-11-20 2023-08-11 Scherer Technologies Llc R P Enlazadores de escisión doble de glicósido para conjugados de anticuerpo y fármaco.
CN116783208A (zh) * 2020-11-20 2023-09-19 R.P.谢勒技术有限责任公司 用于抗体-药物缀合物的糖苷双裂解接头
KR20230133312A (ko) * 2021-01-15 2023-09-19 알.피.쉐러 테크놀러지즈 엘엘씨 캄프토테신 항체-약물 접합체 및 이의 사용 방법
CN116847844A (zh) * 2021-01-15 2023-10-03 R.P.谢勒技术有限责任公司 喜树碱抗体-药物缀合物及其使用方法
MX2023008341A (es) * 2021-01-15 2023-10-04 Scherer Technologies Llc R P Enlazadores de ésteres de doble escisión para conjugados anticuerpo-fármaco.
EP4297798A4 (en) * 2021-02-25 2025-11-12 Allygen Group Targeting Conjugates Comprising Effector Molecules and Their Uses
KR20230165207A (ko) * 2021-03-03 2023-12-05 알.피.쉐러 테크놀러지즈 엘엘씨 항체-약물 접합체용 분지형 링커 및 이의 사용 방법
CN117279662A (zh) * 2021-03-03 2023-12-22 R.P.谢勒技术有限责任公司 用于抗体-药物缀合物的支链接头和其使用方法
KR20240040098A (ko) * 2021-07-30 2024-03-27 알.피.쉐러 테크놀러지즈 엘엘씨 넥틴-4에 특이적인 항체 및 항체 접합체 및 이의 사용방법
KR20250160368A (ko) * 2022-03-23 2025-11-12 알.피.쉐러 테크놀러지즈 엘엘씨 뮤신-1에 특이적인 항체 접합체 및 그의 사용 방법
AU2023396827A1 (en) 2022-12-13 2025-06-19 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
LT4601703T (lt) 2023-04-18 2026-06-25 Astrazeneca Ab Konjugatai, apimantys atskeliamuosius jungtukus
TW202525344A (zh) * 2023-08-15 2025-07-01 瑞典商阿斯特捷利康公司 包含可切割連接子的軛合物
WO2026024545A1 (en) * 2024-07-23 2026-01-29 R.P. Scherer Technologies Peg-carbamate linkers for antibody-drug conjugates and uses thereof
WO2026149165A1 (en) * 2025-01-08 2026-07-16 Beta Pharma, Inc. Novel maytansine derivatives, drug-linker conjugates, antibody conjugates and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081282A1 (en) * 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
WO2018234636A1 (en) * 2017-06-21 2018-12-27 Glykos Finland Oy HYDROPHILIC LINKS AND CONJUGATES THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2988786A4 (en) * 2013-04-22 2016-12-21 Avelas Biosciences Inc COMPOSITIONS FOR SELECTIVE DRUG ADMINISTRATION AND METHOD OF USE
WO2017083306A1 (en) * 2015-11-09 2017-05-18 R.P. Scherer Technologies, Llc Anti-cd22 antibody-maytansine conjugates and methods of use thereof
US10195283B2 (en) * 2016-03-18 2019-02-05 R.P. Scherer Technologies, Llc Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate
WO2019113248A1 (en) * 2017-12-07 2019-06-13 The Regents Of The University Of California Anti-upar antibody-drug conjugates and methods of use thereof
WO2020154437A1 (en) * 2019-01-23 2020-07-30 R.P. Scherer Technologies, Llc Glycoside-containing peptide linkers for antibody-drug conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081282A1 (en) * 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
WO2018234636A1 (en) * 2017-06-21 2018-12-27 Glykos Finland Oy HYDROPHILIC LINKS AND CONJUGATES THEREOF

Also Published As

Publication number Publication date
WO2020154437A1 (en) 2020-07-30
AU2020210919A1 (en) 2021-08-26
CN119896746A (zh) 2025-04-29
EP3914262A4 (en) 2023-01-18
US20220226490A1 (en) 2022-07-21
JP2024170512A (ja) 2024-12-10
CN119896745A (zh) 2025-04-29
JP2022518743A (ja) 2022-03-16
CN113874046A (zh) 2021-12-31
EP3914262A1 (en) 2021-12-01
KR20210119450A (ko) 2021-10-05
JP7861064B2 (ja) 2026-05-18
JP7550768B2 (ja) 2024-09-13
AU2020210919B2 (en) 2026-01-29
CA3127098A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
CN119896746A (zh) 用于抗体-药物缀合物的含有糖苷的肽接头
JP2024503074A (ja) カンプトテシン抗体-薬物コンジュゲート及びその使用方法
JP2024510927A (ja) 抗体-薬物コンジュゲートのための分岐リンカー及びその使用方法
JP2024529466A (ja) 抗体薬物コンジュゲート及びその使用方法
JP2024532302A (ja) 腫瘍関連カルシウムシグナルトランスデューサー2(tacstd2)抗体-メイタンシンコンジュゲート及びその使用方法
US11980668B2 (en) Sulfatase-cleavable linkers for antibody-drug conjugates
CN116847885A (zh) 用于抗体-药物缀合物的双切割酯接头
WO2025064427A1 (en) Dual-payload antibody-drug conjugates and uses thereof
CN120129535A (zh) 组织因子抗体-药物缀合物及其用途
JP2023551203A (ja) 抗体-薬物コンジュゲートのためのグリコシド二重切断リンカー
RU2859790C2 (ru) Сложноэфирные линкеры с двойным расщеплением для конъюгатов антитело-лекарственное средство
CN117279662A (zh) 用于抗体-药物缀合物的支链接头和其使用方法
WO2025064424A1 (en) Tandem-cleavage linkers for antibody-drug conjugates and uses thereof
CN116783208A (zh) 用于抗体-药物缀合物的糖苷双裂解接头
CN118339165A (zh) 抗体-药物缀合物及其使用方法
JP2025513664A (ja) ムチン-1に特異的な抗体コンジュゲート及びその使用方法
CN116847844A (zh) 喜树碱抗体-药物缀合物及其使用方法
WO2026024545A1 (en) Peg-carbamate linkers for antibody-drug conjugates and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: D. Labuka

Inventor after: J.Liu

Inventor after: A. Ogonkoa

Inventor after: R.A. Kudirka

Inventor before: D. Labuka

Inventor before: J.Liu

Inventor before: A. Ogonkoa

CB03 Change of inventor or designer information
GR01 Patent grant
GR01 Patent grant